Many studies have recently used the ultrasensitive single molecule array (Simoa) technology for NFL quantification in MS patients, to assess disease activity and treatment consequence, revealing strong correlations between serum NFL levels, MRI parameters and relapse rate [17,18,19,20,21,22]. The gene discussed is NEFL; the disease is myeloid sarcoma.